Therapeutic Strategies for Duchenne Muscular Dystrophy: An Update.
Sun C, Shen L, Zhang Z, Xie X.
Genes (Basel). 2020 Jul 23;11(8):837. doi: 10.3390/genes11080837.
CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy.
Happi Mbakam C, Lamothe G, Tremblay G, Tremblay JP.
Neurotherapeutics. 2022 Apr;19(3):931-941. doi: 10.1007/s13311-022-01197-9. Epub 2022 Feb 14.
Duchenne Muscular Dystrophy: From Diagnosis to Therapy.
Falzarano MS, Scotton C, Passarelli C, Ferlini A.
Molecules. 2015 Oct 7;20(10):18168-84. doi: 10.3390/molecules201018168.
Exercise Training in Duchenne Muscular Dystrophy: A Systematic Review and Meta-Analysis.
Hammer S, Toussaint M, Vollsæter M, Nesbjørg Tvedt M, Drange Røksund O, Reychler G, Lund H, Andersen T.
J Rehabil Med. 2022 Jan 11;54:jrm00250. doi: 10.2340/jrm.v53.985.
Duchenne muscular dystrophy.
Yiu EM, Kornberg AJ.
J Paediatr Child Health. 2015 Aug;51(8):759-64. doi: 10.1111/jpc.12868. Epub 2015 Mar 9.
[Update on Duchenne muscular dystrophy].
Leiva-Cepas F, Montaño Martínez A, López-López I.
Semergen. 2021 Oct;47(7):472-481. doi: 10.1016/j.semerg.2021.06.008. Epub 2021 Aug 18.
Duchenne muscular dystrophy: promising early-stage clinical trials to watch.
Tang A, Yokota T.
Expert Opin Investig Drugs. 2024 Mar;33(3):201-217. doi: 10.1080/13543784.2024.2313105. Epub 2024 Feb 6.
Delandistrogene moxeparvovec (Elevidys) for Duchenne muscular dystrophy.
[No authors listed]
Med Lett Drugs Ther. 2023 Oct 2;65(1686):159-160. doi: 10.58347/tml.2023.1686d.
The importance of genetic diagnosis for Duchenne muscular dystrophy.
Aartsma-Rus A, Ginjaar IB, Bushby K.
J Med Genet. 2016 Mar;53(3):145-51. doi: 10.1136/jmedgenet-2015-103387. Epub 2016 Jan 11.
Duchenne muscular dystrophy.
Annexstad EJ, Lund-Petersen I, Rasmussen M.
Tidsskr Nor Laegeforen. 2014 Aug 5;134(14):1361-4. doi: 10.4045/tidsskr.13.0836. eCollection 2014 Aug 5.
